Are there safer alternatives or lower doses that preserve muscle in seniors?

Lower doses and slower titration are reasonable, but no trial here shows they preserve muscle in seniors. The one lever with real evidence behind it is protein plus resistance training, and even that is unproven in this exact setting.

The honest answer to "safer alternatives or lower doses" is that the evidence in front of me does not test that. The retrieved records include no head-to-head trial of a lower semaglutide dose versus a standard dose in older adults, and no trial of any alternative drug against semaglutide on muscle or function. What they do show is that the muscle problem is real and partly diet-dependent: a clinically meaningful share of weight lost on GLP-1 drugs can come from lean tissue, especially with low protein intake or little resistance exercise [1]. One review puts the split at roughly 75% fat and 25% muscle per kilogram lost [2].

That same review is blunt about the population you care about. Most incretin trials were done in younger adults, and the older adults who were included are poorly defined in the reporting [2]. It also warns that weight loss in older adults has to be balanced against muscle and bone loss [2]. So the "lower dose" question is not answered by any trial here. It is a plausible harm-reduction move, not a proven one.

The trials that would settle this, a protein-optimized diet plus resistance exercise during GLP-1 therapy with body composition measured, have not been run [1]. GLP-1 trials gave general lifestyle advice but never a structured diet arm, so the eating changes seen were drug-driven, not diet-prescribed [1].

My call: for a senior, the safest bet is the lowest effective dose, slow titration, high protein, and resistance training, but only the last two have any supporting evidence, and it is observational. Confidence: low, because the dose-comparison and older-adult muscle trials do not exist in this evidence.